
Nomura lists four factors that will drive growth for Dr. Reddy’s beyond gRevlimid
The management of Dr. Reddy’s Laboratories expects to deliver double-digit growth, excluding gRevlimid in the base business. This excludes Semaglutide sales.

The management of Dr. Reddy’s Laboratories expects to deliver double-digit growth, excluding gRevlimid in the base business. This excludes Semaglutide sales.

Of the 14 analysts that have coverage on BSE, 10 have a “buy” rating, three have a “hold” rating and one has a “sell” rating.

Shah is watching for a close above 25,200 on the Nifty, which he says could trigger a rally to 26,200, with a possible pause around…

At the interbank foreign exchange, the rupee opened at 85.43 against the greenback before falling to 85.46, up 7 paise from its previous close. The…

Jefferies mentioned that despite the recent rally, property stocks continue to trade in line with their five-year NAV premiums. It believes that visible sales growth…

The consortium has secured a ₹2,631.14-crore contract from BSNL for the BharatNet middle-mile network in Jammu & Kashmir and Ladakh.

The company is expected to execute the order within 90 days from the date of issuance of the work.

In India, the price of 24-karat gold touched ₹99,280 per 10 grams. The 22-karat and 18-karat variants stood at ₹91,000 per 10 grams and ₹74,460…

Rising oil prices are generally beneficial for upstream oil explorers such as Oil India and ONGC as it will result in the increase in prices…

Out of the 35 analysts that have coverage on Tata Motors, 18 of them have a “buy” rating, 11 say “hold”, while six have a…